ArticleNature communications2018
Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 95 papers.
0numbers the graph read from it
0cells of the map it votes in
95citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
95 citing papers in PubMed, 145 citations in OpenAlex.
- Dyslipidaemias in cancer patients.European heart journal · 2026Review
- Article
- Article
- The interplay between lipid metabolism, cancer progression and anti-cancer immunity.Experimental & molecular medicine · 2026Review
- Catestatin peptide impedes melanoma progression and drug resistance by reprogramming oncogenic signaling pathways.Oncogenesis · 2026Article
- Metabolic reprogramming-a breakthrough point in overcoming resistance to BRAF mutant melanoma targeted therapy (Review).Oncology letters · 2026Review
- RYK is a GPNMB receptor that drives MASH.Nature · 2026Article
- BRAF inhibitor resistance in melanoma: from resistance mechanisms to therapeutic innovations.Molecular biomedicine · 2026Review
- Decoding the Role of Lipid Metabolism and Membrane Dynamics in Melanoma.International journal of molecular sciences · 2026Review
- Liver specific-inhibition of LPCAT3 ameliorates metabolic dysfunction-associated steatotic liver disease.Journal of molecular medicine (Berlin, Germany) · 2026Article
- A fungi-derived cyclic peptide enhances Th9-mediated antitumor immunity by targeting ZAP70 and SREBP1.The Journal of clinical investigation · 2026Article
- Lipidomics in Melanoma: Insights into Disease Progression and Therapeutical Targets.International journal of molecular sciences · 2026Review
- Catestatin peptide impedes melanoma progression and drug resistance by reprogramming oncogenic signaling pathways.Research square · 2026Article
- Metabolic adaptations in cancer progression.Physiological reviews · 2026Review
- AMP-activated protein kinase-driven lipid droplet dynamics govern melanoma sensitivity to polyunsaturated fatty acid and iron-induced ferroptosis.Nature communications · 2025Article
- RUNX2 cooperates with SREBP1 to rewire cancer metabolism and promote aggressiveness.Journal of experimental & clinical cancer research : CR · 2025Article
- Catestatin suppresses melanoma progression and drug resistance through multitargeted modulation of signaling pathways.bioRxiv : the preprint server for biology · 2025Article
- Cancer-associated fibroblasts promote drug resistance in ALK-driven lung adenocarcinoma cells by upregulating lipid biosynthesis.Cancer & metabolism · 2025Article
- MARCH8 suppresses hepatocellular carcinoma by promoting SREBP1 degradation and modulating fatty acid de novo synthesis.Cell death & disease · 2025Article
- Article
35 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 4 institutions in 1 country.
Ali TalebiLaboratory of Lipid Metabolism and Cancer, Department of Oncology, LKI-Leuven Cancer Institute, KU Leuven, 3000, Leuven, Belgium.
Jonas DehairsLaboratory of Lipid Metabolism and Cancer, Department of Oncology, LKI-Leuven Cancer Institute, KU Leuven, 3000, Leuven, Belgium.
Florian RambowLaboratory for Molecular Cancer Biology, VIB Center for Cancer Biology, 3000, Leuven, Belgium.
Aljosja RogiersLaboratory for Molecular Cancer Biology, VIB Center for Cancer Biology, 3000, Leuven, Belgium.
David NittnerHistopathology Expertise Center, VIB-KU Leuven Center for Cancer Biology, 3000, Leuven, Belgium.
Rita DeruaLaboratory of Protein Phosphorylation and Proteomics,Department of Cellular and Molecular Medicine, KU Leuven, 3000, Leuven, Belgium.
Frank VanderhoydoncLaboratory of Lipid Metabolism and Cancer, Department of Oncology, LKI-Leuven Cancer Institute, KU Leuven, 3000, Leuven, Belgium.
Joao A G DuarteLaboratory of Cellular Metabolism and Metabolic Regulation, Department of Oncology, LKI-Leuven Cancer Institute, KU Leuven, 3000, Leuven, Belgium.
Francesca BosisioTranslational Cell and Tissue Research, Department of Imaging and Pathology, KU Leuven, Belgium.
Kathleen Van den EyndeTranslational Cell and Tissue Research, Department of Imaging and Pathology, KU Leuven, Belgium.
Kris NysLaboratory of Cell Death Research & Therapy, Department of cellular and molecular medicine, KU Leuven, 3000, Leuven, Belgium.
Mónica Vara PérezLaboratory of Cell Death Research & Therapy, Department of cellular and molecular medicine, KU Leuven, 3000, Leuven, Belgium.
Patrizia AgostinisLaboratory of Cell Death Research & Therapy, Department of cellular and molecular medicine, KU Leuven, 3000, Leuven, Belgium.
Etienne WaelkensLaboratory of Protein Phosphorylation and Proteomics,Department of Cellular and Molecular Medicine, KU Leuven, 3000, Leuven, Belgium.
Joost Van den OordTranslational Cell and Tissue Research, Department of Imaging and Pathology, KU Leuven, Belgium.
Sarah-Maria FendtLaboratory of Cellular Metabolism and Metabolic Regulation, Department of Oncology, LKI-Leuven Cancer Institute, KU Leuven, 3000, Leuven, Belgium.
Jean-Christophe MarineLaboratory for Molecular Cancer Biology, VIB Center for Cancer Biology, 3000, Leuven, Belgium.
Johannes V SwinnenLaboratory of Lipid Metabolism and Cancer, Department of Oncology, LKI-Leuven Cancer Institute, KU Leuven, 3000, Leuven, Belgium. j.swinnen@kuleuven.be.ORCID http://orcid.org/0000-0002-7720-5077
VIB-KU Leuven Center for Cancer Biology · BEKU Leuven · BEUniversitair Ziekenhuis Leuven · BERega Institute for Medical Research · BE
Funding
Fonds Wetenschappelijk Onderzoek (Research Foundation Flanders) G0E0817NKU Leuven (Katholieke Universiteit Leuven) C16/15/073
Abstract
Whereas significant anti-tumor responses are observed in most BRAF
Indexed as
AnimalsAntineoplastic AgentsCell Line, TumorDown-RegulationDrug Resistance, NeoplasmFemaleGene Expression Regulation, NeoplasticGene Knockout TechniquesHumansLipogenesisMaleMelanocytesMelanomaMiceMice, NudeMice, SCIDAntineoplastic AgentsBRAF protein, humanfatostatinProtein Kinase InhibitorsProto-Oncogene Proteins B-rafPyridinesSREBF1 protein, humanSterol Regulatory Element Binding Protein 1ThiazolesVemurafenib
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.